CRISPR Therapeutics

CRSP · Nasdaq · Switzerland

Share price · CRSP

$40.19-12.78 (-24.13%) 3M

close as of 2026-11-18 · 24h delayed · vol 4.0M (2.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CRSP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026-9.8%
  2. 17 Sep 2026+9.8%
  3. 19 Aug 2026+12.9%

    Nothing announced by CRSP that day or the session before.

  4. 2 Jul 2026+8.0%
  5. 5 Jun 2026-9.0%
  6. 4 Jun 2026+9.4%
  7. 24 Apr 2026-11.6%
  8. 10 Mar 2026-10.2%

    Nothing announced by CRSP that day or the session before.

  9. 26 Feb 2026+11.8%

    Nothing announced by CRSP that day or the session before.

  10. 13 Feb 2026+8.5%

Share of unusual movement by asset

For each asset, the share of CRSP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
CTX310
events and moves
4shown from 8 days
Exagamglogene autotemcel (Casgevy) (Casgevy)
events and moves
4shown from 8 days
Zugocabtagene geleucel
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—4%
Other company news (earnings, financing, releases naming no asset)—10%
Sessions with no dated event—86%

Assets

(4 total)
4Total Assets
1Approved
0Phase 3 / Filed
3Phase 1–2 / Early
8Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
BCL11A erythroid enhancer (gene editing)Gene therapy / editing
Sickle Cell DiseaseBeta-Thalassemia
Transfusion-Dependent Beta Thalassemia
Phase 2
Factor XIRNA / oligonucleotide
Atherosclerotic Cardiovascular DiseaseVenous Thromboembolism
Phase 1/2
CD19Cell therapy
Systemic Lupus ErythematosusDiffuse Large B-Cell LymphomaFollicular Lymphoma
Phase 1
ANGPTL3Gene therapy / editing
Atherosclerotic Cardiovascular DiseaseSevere Hypertriglyceridemia

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
June 2027 (2)
Exagamglogene autotemcel (Casgevy)Phase 3Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases
Est. primary completion 2027-06-06 · NCT05329649 · CT.gov ↗
What to watch
Exagamglogene autotemcel (Casgevy)Phase 3Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia
Est. primary completion 2027-06-09 · NCT05477563 · CT.gov ↗
What to watch
November 2027 (1)
Exagamglogene autotemcel (Casgevy)Phase 3Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Est. primary completion 2027-11-14 · NCT05356195 · CT.gov ↗
What to watch
December 2027 (1)
SRSD107Phase 2Coronary Artery Disease (CAD), Peripheral Arterial Disease
Est. primary completion 2027-12 · NCT07318155 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Zugocabtagene geleucelPhase 1/2Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease …
Est. primary completion 2029-12-30 · NCT07804004 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Zugocabtagene geleucelPhase 1/2B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) …
Est. primary completion 2030-01 · NCT05643742 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Zugocabtagene geleucelPhase 1/2Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
Est. primary completion 2033-12 · NCT07549698 · CT.gov ↗
What to watch
2039 (1)
September 2039 (1)
Exagamglogene autotemcel (Casgevy)Phase 3Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia
Est. primary completion 2039-09-30 · NCT04208529 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 July 2026ApprovalExagamglogene autotemcel (Casgevy)FDA approves expanded use of CASGEVY for ages 2 and older
US, FDA · Source ↗
11 June 2026Filing submittedExagamglogene autotemcel (Casgevy)UK submission to expand CASGEVY use to younger children
UK, MHRA · Source ↗
November 2025PresentationCTX310CTX310 first-in-human Phase 1 data presented at AHA 2025
US · CRISPR Therapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$13M$72M$192M+ $2.1B short-term inv.$111M-$90M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$10M$67M$291M+ $2.1B short-term inv.$91M-$84M operating cash flowreport ↗
2026-Q1$1.5M$69M$423M+ $2.0B short-term inv.$123M-$109M operating cash flowreport ↗
2025-Q3$0.9M$59M$287M+ $1.6B short-term inv.$106M-$85M operating cash flowreport ↗
2025-Q2$0.9M$70M$194M+ $1.5B short-term inv.$209M-$114M operating cash flowreport ↗
2025-Q1$0.9M$72M$235M+ $1.6B short-term inv.$136M-$54M operating cash flowreport ↗
2024-Q3$0.6M$82M$226M+ $1.7B short-term inv.$86M-$107M operating cash flowreport ↗
2024-Q2$0.5M$80M$484M+ $1.5B short-term inv.$126M-$96M operating cash flowreport ↗
2024-Q1$0.5M$76M$707M+ $1.4B short-term inv.$117M$110M operating cash flowreport ↗
2023-Q3$0$91M$528M+ $1.2B short-term inv.$112M-$40M operating cash flowreport ↗
2023-Q2$70M$102M$445M+ $1.3B short-term inv.$78M-$133M operating cash flowreport ↗
2023-Q1$100M$100M$344M+ $1.5B short-term inv.$53M$8.8M operating cash flowreport ↗
2022-Q3$0.1M$117M$494M+ $1.4B short-term inv.$175M-$105M operating cash flowreport ↗
2022-Q2$0.2M$123M$497M+ $1.6B short-term inv.$186M-$142M operating cash flowreport ↗
2022-Q1$0.9M$118M$684M+ $1.5B short-term inv.$179M-$135M operating cash flowreport ↗
2021-Q3$0.8M$105M$1.0B+ $1.5B short-term inv.$127M-$81M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.5M$285M$348M+ $1.6B short-term inv.$145M-$345M operating cash flowreport ↗

For FY2025, CRISPR Therapeutics reported revenue of $3.51M, down 90.6% YoY, and R&D spend of $284.81M, down 11.2% YoY. Cash and cash equivalents were $347.56M, while cash, cash equivalents, and marketable securities totaled $1,975.8M at year-end, and the company reported a net loss of $581.6M.

Operationally, CASGEVY generated $116M in full-year 2025 revenue and $54M in Q4 2025, with 64 patient infusions during the year and 147 first cell collections. Pipeline advances included ongoing zugo-cel trials in autoimmune disease and B-cell malignancies, Phase 1b CTX310, CTX321 and CTX340 in IND/CTA-enabling studies, CTX460 in preclinical development, the CTX611 collaboration with Sirius, and CTX213 in diabetes. The company expects CASGEVY pediatric regulatory submissions to begin in H1 2026, CTX340 trial initiation in H1 2026, CTX460 trial initiation in mid-2026, and updates across several programs in H2 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$37M$321M$298M+ $1.6B short-term inv.$92M-$143M operating cash flowreport ↗
2023-FY$371M$387M$389M+ $1.3B short-term inv.$38M-$260M operating cash flowreport ↗
2022-FY$1.2M$462M$212M+ $1.6B short-term inv.$163M-$496M operating cash flowreport ↗
2021-FY$915M$439M$923M+ $1.5B short-term inv.—$539M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 30 sales ($17.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Kulkarni Samarth · director, Chief Executive OfficerGift100,000——Form 4
2026-11-04Sakhamuri Sivakesava · Chief Technical OfficerAward / grant (derivative)90,000——Form 4
2026-11-04Sakhamuri Sivakesava · Chief Technical OfficerAward / grant (derivative)40,000——Form 4
2026-10-26Patel Naimish · Chief Medical OfficerAward / grant (derivative)24,000——Form 4
2026-10-26Kulkarni Samarth · director, Chief Executive OfficerAward / grant (derivative)57,500——Form 4
2026-10-26KASINGER JAMES R. · General Counsel and SecretaryAward / grant (derivative)18,000——Form 4
2026-10-26Silver Andrew Jacob · Chief Financial OfficerAward / grant (derivative)18,000——Form 4
2026-10-26Patel Naimish · Chief Medical OfficerAward / grant (derivative)12,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 487 reporting institutions held 77.1M shares ($3.5B, 80.0% of shares outstanding).

#InstitutionSharesValue
1ARK Investment Management LLC11,313,623$538.2M
2BlackRock, Inc.7,680,073$365.3M
3Orbis Allan Gray Ltd6,106,011$290.5M
4Capital World Investors4,725,037$224.8M
5STATE STREET CORP3,982,500$189.4M
6GSK plc3,220,627$153.2M
7GEODE CAPITAL MANAGEMENT, LLC2,377,164$113.1M
8SR One Capital Management, LP2,038,763$97.0M
9FMR LLC1,954,694$93.0M
10Amova Asset Management Americas, Inc.1,853,875$88.2M
11Sumitomo Mitsui Trust Group, Inc.1,853,875$88.2M
12UBS Group AG1,762,530$83.8M
13TWO SIGMA INVESTMENTS, LP1,483,051$70.5M
14EcoR1 Capital, LLC1,389,276$66.1M
15Capital International Investors1,186,794$56.5M